In addition to the analyst luncheon, the TCT program will include a number of clinical presentations featuring several of Edwards' interventional cardiovascular technologies. Among the presentations are (all times EDT):
Sunday, Oct. 21
-- The Valvular Heart Disease Summit -- 8:00 a.m. to 7:00 p.m., Room
202B, co-sponsored by Edwards. The summit will cover topics including
mitral regurgitation therapies, transcatheter mitral valve repair and
replacement, transcatheter pulmonic valve replacement, aortic stenosis
and new devices. Presentations during the summit include: an overview
of Edwards' transcatheter heart valve replacement program, an update
on the status of the PARTNER pivotal trial for this device and interim
results from the EVOLUTION feasibility study, which utilizes Edwards'
MONARC system, a device intended to treat functional mitral
regurgitation in heart failure patients.
Monday, Oct. 22
-- Advanced Endovascular Techniques for the Treatment of Infrainguinal
Disease -- 7:00 a.m. to 8:00 a.m., Room 149AB, supported through an
educational grant by Edwards. The breakfast meeting will address
techniques and technologies for the treatment of infrainguinal
disease, as well as adjunct therapies.
Tuesday, Oct. 23
-- "Blockbuster" Trial of the Day: RESILIENT -- 11:00 a.m. to 12:00 p.m.,
Main Arena, Ballrooms ABC, Level 3. Presentations will address the
one-year results from the RESILIENT trial, the landmark randomized
study of the Edwards LifeStent Self-Expanding Stent in the SFA.
-- Hot Topics 2007/2008: Regulatory Pathways for Percutaneous Aortic
Valves -- 2:15 p.m. to 2:45 p
|SOURCE Edwards Lifesciences Corporation|
Copyright©2007 PR Newswire.
All rights reserved